Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body composition change after ART transition in people living with HIV
TCTR20240404003Phase 1Unknown
- Sponsor
- Ramathibodi Foundation
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Ramathibodi Foundation. Primary endpoint: Body composition change. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20240404003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240404003.